Welcome to our dedicated page for Ibio news (Ticker: IBIO), a resource for investors and traders seeking the latest updates and insights on Ibio stock.
iBio, Inc. (NASDAQ: IBIO) is an AI-driven biotechnology company developing precision antibody therapies for cardiometabolic diseases, obesity, cancer and other hard-to-treat conditions. The IBIO news feed on Stock Titan aggregates company press releases and other coverage so readers can follow how the business and its preclinical pipeline are evolving over time.
Recent news highlights iBio’s focus on obesity and cardiometabolic disease, including preclinical data for its Activin E antibody candidate IBIO-610 and its long-acting anti-myostatin antibody IBIO-600. The company has reported fat-selective, GLP‑1‑synergistic weight loss in diet-induced obesity mouse models, non-human primate pharmacokinetic data suggesting extended half-life and potential for infrequent dosing, and early evidence that its programs may help preserve lean mass in combination with GLP‑1 therapies. Updates also cover presentations at scientific and investor conferences such as ObesityWeek, PEGS Europe and healthcare-focused investment conferences.
Investors tracking IBIO news will also see announcements about financings, including underwritten public offerings, warrant transactions and private placements with institutional investors, along with disclosures on how proceeds are intended to support preclinical cardiometabolic programs and other pipeline assets. Regulatory and corporate developments reported via Form 8‑K, such as Nasdaq listing compliance notices, annual meeting results and updated corporate presentations, provide additional context on governance and capital markets activity.
By following this IBIO news page, readers can monitor new preclinical data, conference participation, financing transactions and key SEC-reported events that shape iBio’s progress as a preclinical-stage, AI-enabled antibody developer.
iBio (NYSE:IBIO) announced its participation in the 18th Annual Protein & Antibody Engineering Summit in Boston from May 2-5, 2022. The company will showcase research demonstrating that its FastPharming Manufacturing System produces monoclonal antibodies with a uniform G0 glycosylation pattern, unlike traditional CHO cell culture methods, which yield more heterogeneous patterns. The presentation aims to illustrate the efficacy, rapid scalability, and potential time savings in achieving in vivo proof-of-concept for therapeutic applications.
iBio (NYSEA:IBIO) announced its Chairman & CEO, Tom Isett, will present at the Oppenheimer 32nd Annual Healthcare Conference on March 17, 2022, at 2:40 p.m. Eastern Time. This virtual presentation will be broadcasted live and archived on the iBio website under the 'News & Events' section.
iBio is known for its FastPharming Manufacturing System®, focusing on sustainable, plant-based biopharmaceuticals, including treatments for cancers and infectious diseases.
Pipeline Therapeutics announced the appointment of Eef Schimmelpennink to its Board of Directors. With nearly 25 years of experience in the biotechnology sector, he aims to enhance the company’s efforts in neuroregeneration. Schimmelpennink has held prominent roles, including CEO of Pfenex and LENZ Therapeutics. His leadership is expected to advance Pipeline's promising portfolio, which includes two clinical candidates, PIPE-307 and PIPE-505, targeting neurological conditions. This strategic addition to the board could bolster the company's growth trajectory in the biopharmaceutical industry.
iBio, Inc. (NYSEA:IBIO) reported its financial results for the quarter ending December 31, 2021. The company added six new immuno-oncology assets to its pipeline and is advancing its COVID-19 vaccine candidate, IBIO-202, toward clinical trials. Revenues were approximately $0.2 million, a 76% decrease from the previous year, while R&D and G&A expenses increased by 40% and 48%, respectively. The net loss for the quarter was approximately $11.9 million. iBio expects adequate cash to fund operations through September 30, 2023.
iBio, Inc. (NYSEA:IBIO) announced it will report fiscal 2022 second quarter financial results on February 14, 2022, after market close. A conference call will be held at 4:30 PM ET to discuss these results and future corporate updates. iBio specializes in next-generation biopharmaceuticals, utilizing its innovative FastPharming Manufacturing System® for sustainable, plant-based biologics. The company aims to advance treatments for cancers and other diseases through high-quality monoclonal antibodies and proteins.
iBio Updates on IBIO-202 COVID-19 Vaccine Development
iBio, Inc. (IBIO) announced progress on its COVID-19 vaccine, IBIO-202, which targets the nucleocapsid protein. Following FDA feedback, the company will conduct IND-enabling challenge studies and aims to submit an IND application by year-end 2022. This second-generation vaccine seeks to overcome waning immunity associated with first-generation vaccines that focus on the spike protein. iBio's research indicates that the N protein could stimulate a more durable immune response against emerging variants.
iBio, Inc. (NYSE: IBIO) announced its participation in the H.C. Wainwright BioConnect Conference from January 10-13, 2022. The company will provide a pre-recorded presentation accessible to all registered attendees and on its website beginning January 10. iBio specializes in next-generation biopharmaceuticals through its FastPharming Manufacturing System, which integrates vertical farming and automated hydroponics to produce high-quality proteins. The firm is focused on developing biopharmaceuticals for cancer, fibrotic, and infectious diseases.
iBio, Inc. (NYSE: IBIO) has partially adjourned its 2021 Annual Meeting of Shareholders to allow further voting on two key proposals: a Reverse Stock Split and a Change in Authorized Shares. As of now, shareholders are supporting these proposals by a 2-to-1 margin. The Annual Meeting will reconvene on January 31, 2022, at 9:00 a.m. Eastern time. The company encourages those who have not yet voted or who voted against the proposals to reconsider their stance.
iBio, a developer of biopharmaceuticals, announced that its 2021 Annual Shareholders meeting is set for December 22, 2021, at 9:00 AM EST. The meeting will address two critical proposals: a reverse stock split and an increase in authorized shares. Currently, 64% and 67% of shareholders have voted in favor, but additional votes are necessary for approval. iBio encourages shareholders who have not yet voted to participate. The company is recognized for its sustainable, plant-based FastPharming Manufacturing System, aimed at developing treatments for various diseases.
iBio announced the partial adjournment of its annual meeting of stockholders to December 22, 2021, with over 60% of shares voting in favor of a reverse stock split and authorized share decrease. Proposals 4 and 5 received 64% and 67% support, respectively. Both Glass Lewis and ISS recommended approving these measures. The Company aims to secure the requisite majority from all outstanding shares to facilitate its growth strategy while encouraging additional votes from shareholders who have not yet voted.